Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors

por Ma, Yu-Xiang, Liu, Fu-Rong, Zhang, Yang, Chen, Qun, Chen, Zhi-Qiang, Liu, Qian-Wen, Huang, Yan, Yang, Yun-Peng, Fang, Wen-Feng, Xi, Ning, Kang, Ning, Zhuang, Yu-Lei, Zhang, Qi, Jiang, Ying-Zhi, Zhang, Li, Zhao, Hong-Yun
Publicado 2022